- Home
- CGON
CGON
CG ONCOLOGY INC
as 11-15-2024 3:32pm EST
Stocks
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 2.6B | IPO Year: | 2024 |
| Target Price: | $63.88 | AVG Volume (30 days): | 396.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.77 - $50.23 | Next Earning Date: | 11-12-2024 |
| Revenue: | $684,000 | Revenue Growth: | 258.12% |
| Revenue Growth (this year): | 411.76% | Revenue Growth (next year): | 405.27% |
Stock Insider Trading Activity of CG ONCOLOGY INC (CGON)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Song Hong Fang | CGON | Director | Aug 29 '24 | Sell | $35.36 | 650,455 | $23,000,088.80 | 586,982 |
Latest CG ONCOLOGY INC News
CGON Breaking Stock News: Dive into CGON Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
MT Newswires
5 days ago
CG Oncology's Q3 Loss Narrows
GlobeNewswire
5 days ago
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
6 days ago
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
MT Newswires
24 days ago
UBS Initiates CG Oncology With Buy Rating, $60 Price Target
Simply Wall St.
2 months ago
We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth
MT Newswires
2 months ago
RBC Initiates CG Oncology at Outperform, Speculative Risk With $66 Price Target
Insider Monkey
2 months ago
Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock
Compare CGON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CGON CG ONCOLOGY INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.